Andere Kunden interessierten sich auch für
![The Richard and Hinda Rosenthal Lectures 2003]( "The Richard and Hinda Rosenthal Lectures 2003")
The Richard and Hinda Rosenthal Lectures 200337,99 €![Effective Care for High-Need Patients]( "Effective Care for High-Need Patients")
Effective Care for High-Need Patients37,99 €![Developing and Sustaining an Effective and Resilient Oncology Careforce]( "Developing and Sustaining an Effective and Resilient Oncology Careforce")
Developing and Sustaining an Effective and Resilient Oncology Careforce49,99 €![A Review of the HHS Family Planning Program]( "A Review of the HHS Family Planning Program")
A Review of the HHS Family Planning Program72,99 €![The Richard and Hinda Rosenthal Lectures 2004]( "The Richard and Hinda Rosenthal Lectures 2004")
The Richard and Hinda Rosenthal Lectures 200431,99 €![Developing Health Literacy Skills in Children and Youth]( "Developing Health Literacy Skills in Children and Youth")
Developing Health Literacy Skills in Children and Youth65,99 €![Rapid Medicines Management for Healthcare Professionals]( "Rapid Medicines Management for Healthcare Professionals")
Rapid Medicines Management for Healthcare Professionals39,99 €
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.